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Abstract: Infection is the second leading cause of death in patients with cancer. Loss 
of efficacy in antibiotics due to antibiotic resistance in bacteria is an urgent threat 
against the continuing success of cancer therapy. In this review, the authors focus 
on recent updates on the impact of antibiotic resistance in the cancer setting, par-
ticularly on the ESKAPE pathogens (Enterococcus faecium, Staphylococcus aureus, 
Klebsiella pneumoniae, Acinetobacter baumannii, Pseudomonas aeruginosa, and 
Enterobacter spp.). This review highlights the health and financial impact of antibiotic 
resistance in patients with cancer. Furthermore, the authors recommend measures to 
control the emergence of antibiotic resistance, highlighting the risk factors associated 
with cancer care. A lack of data in the etiology of infections, specifically in oncology 
patients in United States, is identified as a concern, and the authors advocate for a 
centralized and specialized surveillance system for patients with cancer to predict 
and prevent the emergence of antibiotic resistance. Finding better ways to predict, 
prevent, and treat antibiotic- resistant infections will have a major positive impact on 
the care of those with cancer. CA Cancer J Clin 2021;0:1-17. © 2021 The Authors. 
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Introduction
Bacterial resistance to penicillin was encountered in patients1 within 2 years after 
mass production of the antibiotic began in 1945.2,3 Since then, the emergence of 
antibiotic resistance has been reported against virtually all antibiotics developed to 
date.4 Organizations such as the World Health Organization (WHO) and the US 
Centers for Disease Control and Prevention (CDC) have recognized antimicrobial 
resistance (AMR) as a global threat.5,6 The misuse and overuse of antibiotics is a 
significant driver for increasing antibiotic resistance.4,7 If the scientific community 
fails to manage and replenish our antibiotic supply, nearly 10 million extra deaths 
are predicted by 2050 due to drug- resistant infections.8- 10 In a postantibiotic era, 
many interventions that we currently take for granted will be threatened. These 
include medical advances that have occurred in general surgery,11 treatment of 
immunocompromised patients,12 organ transplant recipients,13 and patients with 
prosthetic implants.14 Importantly, increasing levels of antibiotic resistance are al-
ready having a profound impact on the care of patients with cancer.15 End cancer 
as we know it is a major priority of the Biden Administration16 as well as medical 
societies,17 but achieving that goal will also require action against drug- resistant 
microbes.
Infections are common in patients with cancer, and they depend upon effective anti-
biotics to both prevent and treat bacterial infections. Antibiotic failure in patients with 
cancer increases the frequency of sepsis, sepsis- related mortality, and sepsis- associated 
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costs of care.18- 23 Thus it is not surprising that oncologists 
have been among the first to point out the clinical impact 
of increasing antibacterial resistance. For example, a recent 
study in the United Kingdom reported that 46% of the on-
cologists in the United Kingdom are worried that chemo-
therapy as a treatment for cancer will be difficult as a result 
of drug- resistant infections.24 Optimizing the use of current 
antibiotics and discovery of novel antibiotics are critically 
important to protect patients with cancer from antibiotic- 
resistant infections in the future because antibiotic resistance 
threatens to undo much of the hard- won progress against 
cancer.25
Antibiotic resistance is defined as the ability of microor-
ganisms to survive when exposed to antibiotics that usually 
would kill them or prevent their growth.26 Some of the key 
factors contributing to antibiotic resistance are misuse of an-
tibiotics in humans and animals, use of antibiotics in animal 
and food industries, lack of rapid diagnosis procedures, and 
the presence of antibiotics in the environment.27 Antibiotic 
resistance can be intrinsic or acquired due to various genetic 
mechanisms. We have highlighted the major mechanisms of 
antibiotic resistance in Table 1.28- 41 Some mechanisms can 
lead to antibiotic resistance in 1 or 2 classes of antibiotics, 
whereas others result in multidrug- resistant (MDR) isolates, 
which are characterized by exhibiting resistance to ≥3 differ-
ent classes of antibiotics.42,43 In 2008, Rice et al designated 
6 groups of bacteria (Enterococcus faecium, Staphylococcus au-
reus, Klebsiella pneumoniae, A. baumannii, Pseudomonas aeru-
ginosa, and Enterobacter spp.) that were commonly associated 
with antibiotic resistance in the hospital environment and 
referred to them as ESKAPE pathogens.44 In this review, 
we focus on recent updates regarding antibiotic- resistant 
ESKAPE infections, including risk factors, antibiotic use, 
management, and prevention of antibiotic resistance in pa-
tients with cancer.
The Use of Antibiotics and the Burden of 
Antibiotic Resistance in Patients With Cancer
Infections are one of the most frequent complications seen in 
patients with cancer,45 and a patient with cancer has a 3 times 
greater risk of dying from a fatal infection than a patient 
without cancer.46 Infections are thought to play a primary or 
associated role in the cause of death in approximately 50% of 
patients with hematological malignancies or solid tumors,47 
even if drug- resistant infections are rarely recorded as the offi-
cial cause of death on death certificates.48 Bacteria are the most 
common cause of infections in patients with cancer.47,49 Risks 
of developing an infection include disruption of anatomic 
barriers,50 surgery,51 chemotherapy- related and radiation- 
related neutropenia,52 and stem cell transplantation.53 More 
recently, an increased risk of infection is reportedly caused by 
toxicity mitigation strategies using newer immunotherapies 
against cancer.54- 56 Under neutropenic conditions, patients 
with cancer are subjected to prolonged treatment of antibiot-
ics prophylactically and empirically.57,58 However, widespread 
and prolonged use of broad- spectrum antibiotics to reduce 
mortality and morbidity from infections in patients with can-
cer are likely contributors to the emergence of resistance.59-
 61 In addition, patients with cancer are vulnerable to health 
care- acquired infections as a major source of antibiotic- 
resistant organisms.32,62,63 We have summarized several stud-
ies in which ESKAPE pathogens were isolated from patients 
with cancer since 2015 in Table 2.31,59- 62,64- 74 These illustrate 
the prevalence of MDR in different ESKAPE pathogens and 
highlight that prior antibiotic exposure and hospital- acquired 
infections are the major risk factors for developing antibiotic 
resistance in patients with cancer. For Figure 1, we derived 
data from the National Healthcare Safety Network (NHSN) 
2015 to 2017 adult and pediatric antibiotic resistance re-
ports75,76 to illustrate differences between the percentage of 
central line- associated bloodstream infections by ESKAPE 
pathogens that tested nonsusceptible to selected antimicro-
bial agents. Vancomycin resistance in E. faecium and fluoro-
quinolone nonsusceptibility in Escherichia coli appear to be 
significantly higher in adult oncology patients compared with 
pediatric patients.
Antibiotic Resistance Is Related to Unfavorable 
Outcomes in Patients With Cancer
Antibiotic resistance leads to detrimental effects in pa-
tients with cancer, who rely on antibiotics to prevent and 
treat infections. Although cancer survivorship has increased 
with the success of modern cancer care, current therapeutic 
approaches continue to make these patients vulnerable to 
infections.77- 79 A meta- analysis by Teillant et al found that, 
in postchemotherapy infections, 26.8% of pathogens were 
identified as resistant to the standard prophylactic antibiot-
ics that had been prescribed. That study forecasted that a 
reduction in antibiotic efficacy of 30% to 70% would result 
in nearly 4000 to 10000 additional infections and 500 to 
1000 additional deaths per year in the United States among 
patients who go through chemotherapy for hematological 
malignancies.15
Multiple studies demonstrate the impact of increasing 
resistance on outcomes in this vulnerable population.80- 82 
Bodro et al reported increased persistence of bacteremia 
(25% vs 9.7%), metastatic infection (8% vs 4%), and early 
case- fatality rates (23% vs 11%) among patients with cancer 
who had infections caused by antibiotic- resistant ESKAPE 
pathogens compared with other bacterial pathogens. Risk 
doi: 10.3322/caac.21697. Available online at cacancerjournal.com
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factors that were associated with having an antibiotic- 
resistant infection included comorbidities, prior antibi-
otic therapy, having a urinary catheter, and a urinary tract 
source of infection. Those authors identified a wide va-
riety of pathogens, including: methicillin- resistant S. 
aureus (MRSA), extended- spectrum β- lactamase (ESBL)– 
producing K. pneumoniae, carbapenem- resistant A. bau-
mannii, carbapenem- resistant and quinolone- resistant P. 
aeruginosa, and de- repression of chromosomal β- lactamase 
and ESBL- producing Enterobacter species.34
A study in 2015 found that 58 of 282 deaths (23%) 
among patients with cancer who required intensive care 
were caused by hospital- acquired infections. In 51 of those 
58 cases (88%), an MDR pathogen was identified. The over-
all prevalence of MDR pathogens was nearly 40% in mi-
croorganisms collected from patients who were admitted to 
the intensive care unit. Of the identified MDR pathogens, 
20% were caused by E. coli (94.4% of these were ESBL pro-
ducers), 12% were caused by S. aureus (90.6% of these were 
MRSA), 12% were caused by E. faecium (18.7% were van-
comycin resistant), and 6% were caused by A. baumannii (all 
were MDR).32
In 109 patients with hematological diseases who were 
undergoing chemotherapy, overall survival at 30 days was 
analyzed in those who had Gram- negative bloodstream 
infections (BSIs). In patients who had infections caused by 
MDR bacteria, survival was significantly lower compared 
with the survival of those who had infections caused by non- 
MDR isolates (85.6% vs 55.9%; P < .001).83 In addition, 
numerous recent studies support the association of antibiotic 
resistance with unfavorable outcomes in patients with both 
hematological malignancies and solid tumors.84- 88 The im-
pact of resistance is not limited to the adult population. In a 
tertiary children’s hospital from 2010 to 2014, carbapenem- 
resistant versus carbapenem- susceptible BSI was associated 
with a longer duration of bacteremia (mean, 3.8 vs 1.7 days), 
a higher risk for intensive care unit hospitalization (44.4% vs 
10.1%), and a higher mortality rate (33% vs 5.8%) in patients 
with hematological malignancies and after hematopoietic 
stem cell transplantation.89
Infections with antibiotic- resistant bacteria have been 
studied less in patients with solid tumors than in those 
with hematological malignancies.90 This could be because 
of a lower incidence of BSIs reported in solid tumors com-
pared with hematological malignancies in neutropenic 
patients with cancer.91 One main difference in infections 
between solid and hematological malignancies is the source 
of infection: pneumonia and urinary tract infections were 
frequent among patients with solid tumors, whereas en-
dogenous sources and catheter- related BSIs were frequent 
in patients with hematological malignancies.91 The risk of 
infection in patients with solid tumors can be increased by 
factors such as chemotherapy- related or radiation therapy- 
related neutropenia, disruption of anatomic barriers from 
medical devices and surgical or diagnostic procedures, and 
obstruction due to primary or metastatic tumors, resulting 
in postobstructive pneumonia, lung abscess, or urinary tract 
infections. Common sites of infection in patients with solid 
tumors include BSIs related to neutropenia and postsurgi-
cal site infections in breast, bone, central nervous system, 
and skin.45 Recent epidemiologic data highlight the high 
prevalence of MDR pathogens in these patients.92- 94 One 
study reported that patients older than 70 years with solid 
tumors had more frequent infections because of MDR or-
ganisms compared with patients younger than 70 years.87 
Another study demonstrated that patients with solid tumors 
were more susceptible to bacteremic cholangitis caused by 
Enterobacteriaceae and E. faecium, highlighting the emer-
gence of MDR as a special concern, especially in patients 
who have a second episode of bacteremia.95 AMR can 
become important even during the diagnostic evaluation 
of solid tumors. For example, recent literature has demon-
strated complications such as increased hospitalization and 
death due to antibiotic- resistant infections after prostate 
FIGURE 1. Antibiotic Resistance Is Common in Patients With Cancer. This bar graph displays the percentage of pathogens reported from adult and pediatric 
central line- associated bloodstream infections (CLABSIs) that tested nonsusceptible (NS) to selected antimicrobial agents in hospital oncology units in the 
United States from 2015 to 2017. Data for the graph were obtained from the National Healthcare Safety Network 2015 to 2017 adult and pediatric antibiotic 
resistance reports. *Klebsiella spp. include K. oxytoca and K. pneumoniae. ESCs indicates extended- spectrum cephalosporins (cefepime, cefotaxime, 
ceftazidime, or ceftriaxone); FQs, fluoroquinolones (ciprofloxacin or levofloxacin); OX/CEFOX/METH, oxacillin, cefoxitin, or methicillin; VRE, vancomycin- 
resistant Enterococcus.
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biopsies.96,97 Extensive use of fluoroquinolone prophylaxis 
may be associated with an increase in resistant E. coli strains, 
which can result in infections after prostate biopsies98; as a 
result, broad- spectrum and longer duration of prophylaxis is 
recommended.96,99 Importantly, targeted antibiotic prophy-
laxis with prebiopsy screening has reduced the number of 
infections after the biopsy.100,101
Cancer and antibiotic resistance also converge to worsen 
health disparities. Certain communities of color in the 
United States, including African American, Latinx, and 
indigenous communities, experience higher cancer inci-
dence and lower survival rates for many types of cancers. 
Many complex factors drive these disparities.102 Similarly, 
experts have identified many reasons to suspect a disparate 
impact of AMR, including differences regarding the use of 
prescribed and nonprescribed antibiotics, barriers to medi-
cal care, higher rates of foreign travel to regions with high 
AMR burden, and more likely employment in food animal 
production.103 Taken together, the joint epidemics of cancer 
and AMR can contribute significantly to persistent health 
inequities.
AMR and the Cost of Treating Cancer
The decline of antibiotic effectiveness due to AMR has im-
posed a massive burden on health care costs, with an increase 
in hospital admissions.104 Antibiotic resistance is estimated 
to cost nearly $20 billion in health care and $35 billion a 
year in lost productivity in the US economy.4,105 The cost of 
treating infections in patients with cancer adds a significant 
amount to the overall cost of cancer treatment. For example, 
of all- cause health care costs during first- line chemotherapy, 
neutropenia- related costs accounted for 32.2% in patients 
with non- small lung cancer who were diagnosed with fe-
brile neutropenia.106 On the basis of a study published with 
91,560 and 16,859 cancer- related neutropenia hospitaliza-
tions among adults and children, respectively, the cost of 
cancer- related neutropenia hospitalization was $24,770 per 
stay for adults and $26,000 per stay for children in the United 
States.107 Tori et al reported that the cost of treatment for an 
episode of febrile neutropenia after chemotherapy, on aver-
age, was from $50,000 to $60,000 in 2020.108
Although studies have estimated the increased cost of 
health care caused by AMR, the direct costs of AMR re-
lated to cancer therapy have rarely been studied. In 2004, 
Watters et al reported the cost associated with the treatment 
of patients with head and neck cancer who become colo-
nized or infected with MRSA after major surgical proce-
dures. Patients who were colonized or infected with MRSA 
had up to a 3 times more prolonged hospital stay compared 
with those who were not positive for MRSA. Furthermore, 
the authors reported that the cost of antibiotics increased by 
£2470 per patient because of MRSA.109
Strategies for Preventing Antibiotic Resistance 
in Patients With Cancer
Prevention of Infection— Minimizing Antibiotic 
Usage
Antibiotic prophylaxis is a common practice for prevent-
ing infections and infection- related complications under 
neutropenic conditions in patients who have cancer.110,111 
With neutropenic conditions, patients are prone to develop 
fever (febrile neutropenia), indicating possible infection. 
The mortality rate can go up to 11% in patients who have 
cancer with febrile neutropenia112,113 and can be as high as 
50% during severe sepsis conditions.114 According to some 
studies, prophylactic use of quinolones reduces the incidence 
of fever, probable infections, hospitalizations,115,116 and the 
overall mortality rate.110,117 These gains must be balanced 
with observations that patients with cancer who receive 
prolonged antibiotic prophylaxis are at risk for develop-
ing breakthrough antibiotic- resistant infections.67,118- 120 
Previous antibiotic exposure has been recognized as one of 
the main risk factors for AMR development in some pa-
tients with cancer.59- 61,67 In fact, there remains ongoing de-
bate in clinical oncology settings about the overall use or 
duration of quinolone prophylaxis in some patients with 
cancer because the procedure failed to reduce overall mortal-
ity and increased the emergence of resistant strains in some 
studies.121- 124
Minimizing infections provides an opportunity to re-
duce the use of antibiotics in patients with cancer who have 
neutropenia or those undergoing surgeries and other inva-
sive procedures. The CDC, the American Cancer Society, 
and the National Comprehensive Cancer Network provide 
guidance to patients with cancer, caregivers, and their health 
care teams to prevent infections in patients who have can-
cer. These include educating patients and caregivers about 
day- to- day good practices to prevent infections or to detect 
infections early.125- 127
Antibiotic or chemotherapy administration can result 
in gut microbiota dysbiosis, altering the diversity of bacte-
ria.128- 130 Dysbiosis in the gut microbiota can increase the 
risk for resistance bacteria in the microbiota,131 invasive 
infections,50 post- transplant complications (such as graft- 
versus- host disease in those who undergo hematopoietic 
stem cell transplantation),132 and reduced efficacy in pa-
tients who have cancer treated with immunotherapy.133 
Monitoring gut microbiota for its composition, adminis-
tering protective commensal bacteria to reduce antibiotic- 
resistant infections, and promoting a healthy microbiome 
could be promising approaches for preventing antibiotic re-
sistance, minimizing antibiotic use, and leading to positive 
outcomes in these patients.134- 136
Another area of concern for patients with cancer is the 
recognition that there is geographical variability in antibiotic 
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resistance. Resistance to antibiotics frequently originates in 
one locality, only to spread to others. For example, vancomycin- 
resistant Enterococci was identified in 1987 in Europe and, 
within 10 years, it represented >25% of Enterococci associated 
with BSIs in hospitalized patients in the United States.137 
A study by Arcilla et al in 2017 found that 34.3% of 1847 
travelers who were ESBL- negative before traveling from 
the Netherlands had acquired ESBL Enterobacterales during 
their international travel, with examples of transmission 
within households.138 Furthermore, medical tourists travel 
between health facilities in locations with different rates 
of antibiotic resistance, potentially disseminating resistant 
pathogens.139 With international travel poised to rebound 
after COVID- 19, vulnerable groups such as patients with 
cancer should remain aware of infectious risks, including in-
formation on the prevalence of drug- resistant pathogens that 
might be present in the locations to which they travel.
Promoting the appropriate use of antibiotics among 
health care practitioners and patients will prevent the misuse 
and overuse of antibiotics as well as decreasing costs.140- 142 
Most importantly, this will allow for continued use of the ex-
isting antibiotic armamentarium.143- 145 The required dura-
tion of antibiotic therapy is inexact and has been disputed in 
oncology settings, leading to unnecessarily extended courses 
of antibiotics and heterogeneity of use between practice 
sites.146- 148 Well defined guidelines are required after com-
prehensive studies to establish the optimal duration of antibi-
otic administration to reduce antibiotic overuse in oncology 
settings.149 For example, vancomycin has been shown to be 
inappropriately prescribed as empirical treatment resulting in 
vancomycin resistance.150 Fever and neutropenia guidelines 
published by the Infectious Diseases Society of America in-
dicate that vancomycin is not recommended as a standard 
part of the initial antibiotic regimen for fever and neutrope-
nia and should be considered for specific clinical indications. 
Furthermore, these guidelines emphasize the importance of 
discontinuing vancomycin in the absence of Gram- positive 
organisms.151 Antibiotic de- escalation and discontinuation 
should be considered when the patient is stabilized or the 
causative agent is determined to reduce overuse.152 Early 
discontinuation of empirical antibacterial therapy in patients 
with fever of unknown origin has been demonstrated to be 
safe,153,154 and emerging data indicate that continuation of 
empirical antibiotics until absolute neutrophil count recovery 
could be unnecessary.155,156 De- escalating and discontinua-
tion strategies have been successfully demonstrated in high- 
risk neutropenic patients who have cancer, with a significant 
reduction in antibiotic use.157- 159
Antibiotic Stewardship to Optimize Antibiotic Use
Antimicrobial stewardship has been defined as selection of 
the best antimicrobial treatment at the optimal dose and 
duration, resulting in the best clinical outcome for treating 
and preventing infection with minimal toxicity and a mini-
mal effect on subsequent resistance.160,161
In health care settings, antimicrobial stewardship teams, 
ideally led by infectious diseases physicians in partnership 
with infectious diseases pharmacists, clinical microbiolo-
gists, and infection preventionists, are charged with this 
important initiative. Antimicrobial stewardship is especially 
important for patients with cancer and/or those undergoing 
hematopoietic stem cell transplantation, who are prone to 
serious infections and receive multiple courses of antimi-
crobial therapy during the treatment process.162 These pa-
tients may have the most potential to benefit from antibiotic 
stewardship because past antibiotic exposure is a critical risk 
factor for developing an antibiotic- resistant infection. As 
discussed above, patients who have cancer with antibiotic- 
resistant infections have worse outcomes than those who 
have antibiotic- susceptible infections.163 Rosa et al evalu-
ated patient outcomes related to antibiotic stewardship in 
patients with febrile neutropenia, specifically, mortality in 
those with hematological malignancies and solid tumors. 
Their study indicated that adherence to antibiotic steward-
ship was independently associated with lower mortality.164 
However, according to a review published by Pillinger et al 
in 2020, these patient populations are frequently excluded 
from studies of antibiotic stewardship, and more efforts 
are needed to determine the broader impact of different 
stewardship strategies in this vulnerable patient popula-
tion.165 Nevertheless, several other studies in hospital- wide 
intervention programs have demonstrated the impact of 
antibiotic stewardship on decreasing antibiotic resistance 
system wide and reducing antimicrobial expenditures.166- 170 
Although more data in this patient population are needed, 
it is reasonable to conclude that decreases in infections 
caused by antibiotic- resistant pathogens in a health care sys-
tem would translate to improved outcomes across a diverse 
range of patient populations. The Centers for Medicare and 
Medicaid Services require acute care hospitals and long- 
term care facilities to have antibiotic stewardship programs 
in place, but their impact is uneven because many hospitals 
lack sufficient resources to fully implement stewardship pro-
tocols.171 Only recently has stewardship become a focus in 
outpatient settings, where high levels of inappropriate an-
tibiotic prescriptions persist. Recently implemented Core 
Elements of Outpatient Antibiotic Stewardship by the CDC 
focus on a framework for antibiotic stewardship for outpa-
tient clinicians and facilities that routinely provide antibiotic 
treatment.172 Increased resources will be critical to the uni-
versal adoption of stewardship, and patients at greatest risk 
for increased morbidity and mortality because of antibiotic- 
resistant infections— such as those with cancer— have the 
most to gain.173
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Other than health care settings, it is important to focus 
on more general areas that contribute to the occurrence of 
antibiotic- resistant bacteria. Agriculture, such as the live-
stock and poultry industries,174 is one important area of 
concern. These industries consume large quantities of anti-
biotics to protect animals from infection and also to promote 
growth.175,176 According to the 2019 Summary Report on 
Antimicrobials Sold or Distributed for Use in Food- Producing 
Animals by the US Food and Drug Administration, 54% of 
nearly 11 metric tons of antibiotics used in animal agricul-
ture are medically important, such as tetracyclines and pen-
icillins.174 Antibiotic- resistant bacteria occurring in these 
settings can be transmitted to humans.177- 179 Although no 
studies have been performed to correlate antibiotic resis-
tance in farm animals and patients with cancer, it is likely 
that such patients could face complications because of col-
onization of antibiotic- resistant species in their intestines. 
Tackling antibiotic resistance will require a sustained, multi-
faceted approach in numerous segments of society.
Antibiotic- Resistance Surveillance Systems for 
Patients With Cancer: Prediction and Prevention of 
Outbreaks
The CDC has defined surveillance as systematic, ongoing 
collection, analysis, and interpretation of health data essen-
tial for planning, implementing, and evaluating public health 
practice integrated closely with timely dissemination to those 
who need the data.180 Various countries have developed their 
own guidelines for the surveillance of antibiotic- resistant 
bacteria.181- 183 Surveillance of AMR involves the tracking 
and analysis of antibiotic- susceptibility test results in bacteria 
isolated from clinical samples. These results, combined with 
clinical and demographic data obtained from patients, en-
able clinicians to provide meaningful interventions to reduce 
the burden of antibiotic resistance.184 Surveillance data can 
be used for predictions. The data from surveillance, merged 
with other risk factors, can be used to develop prediction 
models for antibiotic- resistance development in clinically 
relevant bacterial pathogens. In 2020, Gudiol et al developed 
a clinical prediction model available online that could iden-
tify neutropenic patients with cancer who are at high risk of 
bloodstream infections because of MDR P. aeruginosa, cen-
tered on parameters such as patient age and prior antibiotic 
use. Although the study has not been replicated yet by other 
groups, the investigators reported good prediction results in 
patients with cancer from across 34 centers in 12 countries, 
indicating that the model may benefit these patients by im-
proving the administration of specific empirical antibiotic 
treatment and that it may also help optimize the effective-
ness of antibiotic stewardship programs.67 A comprehensive 
and predictive model of ESKAPE pathogens theoretically 
could be a useful tool for predicting the emergence of antibi-
otic resistance in oncology settings and driving the efficient 
utilization of antibiotics. The CDC has increased antibiotic- 
resistance surveillance in accordance with the first National 
Action Plan for Combating Antibiotic Resistant Bacteria, but 
significant gaps in our knowledge remain.185 For exam-
ple, adult and pediatric antibiotic- resistance reports issued 
from 2015 to 2017 by the NHSN highlighted health care- 
associated infections from 17 adult and 8 pediatric oncology 
facilities only. The number of oncology facilities that reported 
data was relatively low compared with the total number of 
health care facilities that reported data in the NHSN (5626 
adult centers and 2545 pediatric centers).75,76 Furthermore, 
the report separately revealed the percentage of antibiotic 
non- susceptible pathogens recorded from oncology units, as 
summarized in Figure 1. A comparison of the percentage of 
non- susceptible pathogens between adult and pediatric on-
cology units reveals higher levels of vancomycin- resistant E. 
faecium and fluoroquinolone- resistant E. coli. However, simi-
lar data were not found for oncology facilities from previous 
reports by the NHSN, so comparisons from previous years 
could not be made.186- 189 Having chronological surveillance 
data on antibiotic resistance in oncology settings will be 
critical for tracking trends and linking rates of resistance to 
interventions made in these patients. Ongoing and future 
efforts by the CDC will help in this regard.
Future Innovations in Antibiotics and Their 
Impact on Resistance
Although several international and governmen-
tal organizations have helped fund new efforts, such as 
CARB- X (Combating Antibiotic- Resistant Bacteria 
Biopharmaceutical Accelerator), to spur the development of 
innovative antibiotics,190 several expert reports have warned 
that antibiotic business models are uniquely broken and re-
quire significant reform to bring innovative new antibacteri-
als to patients.191- 195 Because physicians frequently reserve 
new antibiotics as a last resort treatment for infections, this 
results in a low volume of sales.4 An analysis by Towse et al 
in 2017 estimated that the cost of developing an antibiotic is 
approximately US$1581 million, whereas the average annual 
revenue from an antibiotic’s sales is roughly $46 million.196 
This results in significant obstacles for the pharmaceutical 
industry to developing new antibiotics.4 A predictable return 
on investment for antibiotic development will likely require 
the support of the federal government enacting policies that 
could help prevent the collapse of the antibiotic pipeline. 
Financial incentives for antibiotic innovation should target 
drugs that will provide the most clinical benefit for patients 
with the most significant unmet medical needs.197
The vast majority of antibiotics used clinically are broad- 
spectrum. Broad- spectrum antibiotics are usually active 
against multiple bacterial species, not just the specific patho-
gen that might be targeted in a particular patient scenario.198 
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One major drawback of broad- spectrum antibiotics is the de-
velopment of AMR not only in pathogenic bacteria but also 
in the non- pathogenic commensal bacteria that comprise the 
normal microbiome.199 The development of narrow- spectrum 
antibiotics is considered an attractive approach to overcoming 
antibiotic- resistant bacterial infections because more specific 
antibiotics can reduce the selection pressure in non- targeted 
pathogens.200,201 Examples of experimental narrow- spectrum 
antibiotics for ESKAPE pathogens include bacterio-
phages,202,203 monoclonal antibodies,204 bacteriocins,205,206 
and antisense molecules, such as peptide- conjugated phospho-
rodiamidate morpholino oligomers.207- 209 Bacteriophages are 
bacterial viruses that infect bacterial cells, which can cause the 
bacterium to lyse.210 Bacteriophages are specific for bacteria 
and selectively attach to specific receptors on the surface of the 
host cell.211 Similar to phages, human monoclonal antibodies 
also can be developed for specific bacteria and can be targeted 
by the immune system.212,213 Bacteriocins are peptides of dif-
ferent sizes produced by various bacteria that exhibit bacteri-
cidal activity against other bacteria.205,214 Bacteriocins bind 
various receptors on the surface of the target bacteria to trig-
ger bactericidal effects.215 Phosphorodiamidate morpholino 
oligomers are designed to target mRNA and block translation 
of the gene of interest.207 Continuing advances in the rapid 
identification of pathogens will enable the opportunity of 
using narrow- spectrum antibiotics. Recent developments in 
diagnostic tests, such as next- generation sequencing,36,216- 218 
matrix- assisted laser desorption ionization– time- of- flight 
mass spectrometry,219 and rapid antigen testing,220 have made 
the prospect of pathogen- specific therapy a viable strategy. 
Additional policies are needed to strengthen diagnostic inno-
vation and clinical integration of diagnostics, including better 
outcomes studies to inform clinical use and justify appropriate 
reimbursement.221 Recently, the Infectious Diseases Society 
of America issued new guidelines to treat antimicrobial- 
resistant, Gram- negative infections focusing on the efficiency 
of different antibiotics according to the etiology of the infec-
tion. These guidelines provide preferred or alternative anti-
biotic treatment options with dosages for ESBL- producing 
Enterobacterales, carbapenem- resistant Enterobacterales, and 
difficult- to- treat P. aeruginosa according to the source of 
infection.222
Conclusion
Drug- resistant infections are growing in number and cost 
and significantly threaten our ability to care for patients with 
cancer. The cancer community— patients, loved ones, clini-
cians, and scientists— have successfully advocated for sig-
nificant investments in research and public health strategies 
to prevent cancer and increase therapeutic options, with the 
goal of saving and extending lives.223 Because antibiotic re-
sistance threatens to undo much of this hard- won progress, 
cancer advocates should consider focusing their considerable 
political power on this public health crisis. Cancer and infec-
tious diseases experts must unite to drive the federal policy 
changes necessary to prevent, diagnose, and treat drug- 
resistant infections and to protect the gains that have been 
made against cancer over the past few decades. ■
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